These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38999301)

  • 1. Inotropic Agents: Are We Still in the Middle of Nowhere?
    Iorio AM; Lucà F; Pozzi A; Rao CM; Di Fusco SA; Colivicchi F; Grimaldi M; Oliva F; Gulizia MM
    J Clin Med; 2024 Jun; 13(13):. PubMed ID: 38999301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit.
    Jentzer JC; Coons JC; Link CB; Schmidhofer M
    J Cardiovasc Pharmacol Ther; 2015 May; 20(3):249-60. PubMed ID: 25432872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of cardiovascular drugs in children. Inotropes and vasopressors.
    Steinberg C; Notterman DA
    Clin Pharmacokinet; 1994 Nov; 27(5):345-67. PubMed ID: 7851053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiogenic shock: Inotropes and vasopressors.
    Amado J; Gago P; Santos W; Mimoso J; de Jesus I
    Rev Port Cardiol; 2016 Dec; 35(12):681-695. PubMed ID: 27836218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Vasopressors and inotropes: use in paediatrics].
    García-Canales A; Peña-Juárez RA; Sandoval-Franco LM
    Arch Cardiol Mex; 2018; 88(1):39-50. PubMed ID: 28336302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inotropic therapy for heart failure: an evidence-based approach.
    Felker GM; O'Connor CM
    Am Heart J; 2001 Sep; 142(3):393-401. PubMed ID: 11526351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outpatient parenteral inotropic therapy for advanced heart failure.
    Young JB; Moen EK
    J Heart Lung Transplant; 2000 Aug; 19(8 Suppl):S49-57. PubMed ID: 11016488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasoactive-Inotropic Score: Evolution, Clinical Utility, and Pitfalls.
    Belletti A; Lerose CC; Zangrillo A; Landoni G
    J Cardiothorac Vasc Anesth; 2021 Oct; 35(10):3067-3077. PubMed ID: 33069558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergent management of the airway. New pharmacology and the control of comorbidities in cardiac disease, ischemia, and valvular heart disease.
    Horak J; Weiss S
    Crit Care Clin; 2000 Jul; 16(3):411-27. PubMed ID: 10941581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of novel inotropic agents in the treatment of heart failure.
    LeJemtel TH; Keren G; Reis D; Sonnenblick EH
    J Cardiovasc Pharmacol; 1986; 8 Suppl 9():S47-54. PubMed ID: 2433542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Inotropic Agents in Treatment of Systolic Heart Failure.
    Tariq S; Aronow WS
    Int J Mol Sci; 2015 Dec; 16(12):29060-8. PubMed ID: 26690127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute hemodynamic effects of digoxin alone or in combination with other vasoactive agents in patients with congestive heart failure.
    Tisdale JE; Gheorghiade M
    Am J Cardiol; 1992 Jun; 69(18):34G-47G. PubMed ID: 1626491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis.
    Thackray S; Easthaugh J; Freemantle N; Cleland JG
    Eur J Heart Fail; 2002 Aug; 4(4):515-29. PubMed ID: 12167393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamic effects of ivabradine use in combination with intravenous inotropic therapy in advanced heart failure.
    Elzeneini M; Aranda JM; Al-Ani M; Ahmed MM; Parker AM; Vilaro JR
    Heart Fail Rev; 2021 Mar; 26(2):355-361. PubMed ID: 32997214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel approach to the development of positive inotropic agents for chronic heart failure.
    Packer M
    J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S52-6. PubMed ID: 8907131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Present and future trends in research and clinical applications of inodilators.
    Cargnelli G; Piovan D; Bova S; Padrini R; Ferrari M
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S124-32. PubMed ID: 2483438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The medical treatment of cardiogenic shock: cardiovascular drugs.
    De Backer D; Arias Ortiz J; Levy B
    Curr Opin Crit Care; 2021 Aug; 27(4):426-432. PubMed ID: 33797431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inotrope therapy in acute heart failure: a critical review of clinical and scientific evidence for levosimendan in the context of traditional treatment].
    Ambrosio G; Di Lenarda A; Fedele F; Gabrielli D; Metra M; Oliva F; Perna G; Senni M; De Maria R
    G Ital Cardiol (Rome); 2009 Jul; 10(7):422-33. PubMed ID: 19761100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current and future status of inotropes in heart failure management.
    Arfaras-Melainis A; Ventoulis I; Polyzogopoulou E; Boultadakis A; Parissis J
    Expert Rev Cardiovasc Ther; 2023; 21(8):573-585. PubMed ID: 37458248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac drugs: new inotropes.
    Kelleher RM
    Crit Care Nurs Clin North Am; 1989 Jun; 1(2):391-7. PubMed ID: 2818883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.